New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
16:17 EDTESPRAisling Capital II reports 13.8% passive stake in Esperion Therapeutics
News For ESPR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
16:23 EDTESPROn The Fly: Top stock stories for Monday
Subscribe for More Information
August 27, 2015
18:52 EDTESPROn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTESPREsperion up 1.9% after FDA approves Amgen cholesterol drug Repatha
Subscribe for More Information
August 19, 2015
14:23 EDTESPREsperion continues decline after Needham downgrade
Shares of Esperion (ESPR) are continuing Tuesday's losses following a downgrade this morning from Needham, with the research firm commenting that the company's cholesterol drug may debut against a somewhat thin addressable treatment population. WHAT'S NEW: Needham's Chad Messer issued a research note on Esperion Therapeutics (ESPR), downgrading the stock to Buy from Strong Buy and cutting his price target to $115 from $130. Messer said that "an important catalyst has passed" for the stock following an update Monday on Esperion's ETC-1002 cholesterol treatment. Additionally, Messer noted that while the FDA will not require a cardiovascular outcomes trial, the drug appears to be headed for a smaller-than-expected initial treatment population. WHAT'S NOTABLE: The Needham downgrade follows commentary from JPMorgan on Tuesday, with analyst Jessica Fye remarking that the good news outweighs the bad for Esperion despite the potentially narrower ETC-1002 label. Research firm Chardan did not appear to share those sentiments, countering that the FDA guidance shared by Esperion on Monday is "clearly inconsistent with recent management and consensus commentary." PRICE ACTION: Esperion shares saw gains of about 10% immediately following Monday's update, but later fell throughout Tuesday and into Wednesday. In intra--day trading Wednesday, shares of the company are down about 10%.
13:30 EDTESPROn The Fly: Top stock stories at midday
Subscribe for More Information
10:00 EDTESPROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:19 EDTESPROn The Fly: Pre-market Movers
Subscribe for More Information
07:26 EDTESPREsperion downgraded to Buy from Strong Buy at Needham
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use